Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease. The company's lead product, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor intended to treat anemia associated with chronic kidney disease. Akebia aims to address unmet medical needs in renal conditions through innovative treatments.
Company News
Akebia Therapeutics' Chief Commercial Officer Nik Grund will participate in a Fireside Chat at the 4th Annual Kidney Virtual Conference on July 14, 2025, discussing the company's kidney disease research and developments.
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company said it sees full-year 2024 demand growth of 12% to 14% and revenue growth of 8% to 10% on a year-over-year basis, according to dat...
Analysts say these are penny stocks to buy but are they worth the risk? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.